NASDAQ: CODX · Industrial Applications and Services · 11 alerts · CIK 1692415
Share price
$0.2249Close, Nov 16
Market cap
$2.36M
Shares outstanding
10.51MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Co-Diagnostics, Inc. filings on SEC EDGAR ↗
Co-Diagnostics held a court-ordered special meeting of shareholders on November 13, 2026, where shareholders elected five directors and approved an amendment to the 2025 Equity Incentive Plan. The amendment increases the number of shares authorized for issuance under the plan by 2,000,000 shares, bringing the total maximum to 2,223,333 shares. Shareholders also approved a non-binding advisory resolution regarding executive compensation.
Co-Diagnostics, Inc. reported a net loss of $21.7 million for the nine months ended September 30, 2026, compared to a $21.2 million loss in the prior year. Total revenue increased to $594,966 from $358,567, while cash and cash equivalents significantly decreased to $714,803 from $11.9 million at the start of the year.
Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.
Co-Diagnostics, Inc. reconvened its 2026 Annual Meeting of Stockholders on October 14, 2026, but was unable to transact business because a quorum was not present. The company determined not to adjourn the meeting again and intends to seek stockholder approval for the proposals at a future special meeting.
Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.
Co-Diagnostics, Inc. entered into a loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million, with an initial $2.1 million funded at closing. The debt is structured as senior secured convertible installment promissory notes with a 1.35x factor rate, payable in 30 weekly installments and secured by substantially all company assets.
Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.
Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million. The initial funding of $2.1 million resulted in a promissory note with an original principal amount of $2.835 million, reflecting a 1.35x factor rate, and is secured by substantially all of the company's assets.
Co-Diagnostics, Inc. announced that its 2026 Annual Meeting of Stockholders has been adjourned for a third time to October 14, 2026, due to a failure to achieve a quorum. The company was unable to transact any business at the original September 3 meeting or the subsequent adjournments on September 24 and September 30. Stockholders of record as of the original July 14, 2026 record date remain eligible to vote at the reconvened meeting.
Co-Diagnostics, Inc. has postponed its Annual Meeting of Stockholders for a second time after failing to achieve a quorum on September 24, 2026. The meeting has been rescheduled for September 30, 2026, at the company's offices in Salt Lake City, Utah.
Co-Diagnostics, Inc. is hosting an investor and analyst presentation to discuss its Co-Dx PCR platform, manufacturing initiatives, and operations in India. The presentation also highlights the company's collaboration with ReadyGo Diagnostics Ltd. regarding development activities.
Co-Diagnostics Research Collaboration with ReadyGo Diagnostics Ltd.
Co-Diagnostics and ReadyGo Diagnostics are collaborating to evaluate the integration of ReadyGo's GoCollect sample-preparation technology with the Co-Dx PCR platform. The initial focus is on decentralized Ebola virus detection, with the goal of expanding the platform's capabilities to blood-based molecular testing for pathogens like HIV and hepatitis B and C.
Co-Diagnostics Research Collaboration with ReadyGo Diagnostics Ltd
Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate the compatibility of ReadyGo's sample collection and preparation technologies with the Co-Dx PCR platform. The collaboration involves feasibility studies and compatibility testing to potentially streamline the sample-to-result workflow for decentralized and point-of-care testing. The agreement is preliminary and does not obligate either party to enter into a formal commercial or development arrangement.